Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery
Status:
Completed
Trial end date:
2021-03-02
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blinded, placebo-controlled trial of liraglutide versus placebo
over a follow-up period of 12 months in patients at least 18 months following Roux-en-Y
gastric bypass (RYGB) who are experiencing weight regain. This study will assess the efficacy
of liraglutide in improving cardiometabolic risk profile (as indicated by serum lipids,
HbA1c, and waist circumference) and quality of life (as assessed by PHQ-9 (Patient Health
Questionnaire), versus placebo in patients at least 18 months following RYGB who are
experiencing weight regain as well as the safety of liraglutide in this patient population.
Phase:
Phase 4
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health